Type 1 diabetes mellitus treatment adjunct

Type 1 diabetes mellitus treatment adjunct refers to the use of non-insulin therapeutic agents co-administered alongside primary mealtime and basal insulin therapy in individuals with type 1 diabetes mellitus

Type 1 diabetes mellitus treatment adjunct refers to the use of non-insulin therapeutic agents co-administered alongside primary mealtime and basal insulin therapy in individuals with type 1 diabetes mellitus This endocrine and metabolic disease is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency, co-secreted hormone deficits such as amylin, and subsequent persistent hyperglycemia This adjunctive treatment setting specifically applies to ...

Type 1 diabetes mellitus treatment adjunct refers to the use of non-insulin therapeutic agents co-administered alongside primary mealtime and basal insulin therapy in individuals with type 1 diabetes mellitus This endocrine and metabolic disease is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency, co-secreted hormone deficits such as amylin, and subsequent persistent hyperglycemia This adjunctive treatment setting specifically applies to ...

This endocrine and metabolic disease is characterized by autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency, co-secreted hormone deficits such as amylin, and subsequent persistent hyperglycemia

This adjunctive treatment setting specifically applies to pediatric or adult patients who continue to experience suboptimal glycemic control, elevated glycated hemoglobin levels, pronounced postprandial glucose excursions, or therapy-limiting glycemic variability despite receiving intensive, optimized insulin regimens